Prostate Cancer Clinical Trial
— HIM-UPOfficial title:
Health Interventions in Men Undergoing Radical Prostatectomy- A Randomized Controlled Clinical Trial
Verified date | January 2017 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of the study is to assess the impact of a health intervention, involving both diet and exercise modification, on outcomes following radical prostatectomy for the treatment of clinically localized prostate cancer. The specific urological outcomes expected to be improved are accelerated and/or improved recovery of erectile function (EF), as well as urinary continence, both very commonly affected by this surgery. Furthermore, as demonstrated by changes in responses to various questionnaires, an improvement in overall health-related quality of life is expected. Finally, an improvement in patients participating in the intervention groups in physical parameters, including body mass index (BMI), blood pressure (BP), and metabolic parameters, including serum glucose and cholesterol levels, is expected.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | July 2014 |
Est. primary completion date | July 2014 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 40 Years to 65 Years |
Eligibility |
Inclusion Criteria: - men 40-65 years of age - localized prostate cancer (clinical stage < T2b, Gleason grade < 7, pre-operative prostate specific antigen (PSA) < 10) - scheduled to undergo curative nerve-sparing prostatectomy at the Johns Hopkins Hospital Exclusion Criteria: - in a stable relationship for at least 6 months - moderately to severely impaired preoperative erectile function (IIEF-erectile function domain score < 16) - answering less than 2-3 times or > to question #6 on the IIEF - severe lower urinary tract symptoms International Prostate Symptom Score (IPSS) >20 |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins Hospital | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in erectile function (EF) | The International Index of Erectile Function (IIEF) will be administered. This is a 15 item questionnaire . The questionnaire measures Erectile Function (scored from 0-30), Intercourse satisfaction (0-15), orgasmic function (0-10), Sexual Desire (2-10) and Overall satisfaction (2-10). | From baseline (4 weeks before surgery) to 3 months after surgery | |
Primary | Change in EF | The International Index of Erectile Function (IIEF) will be administered. This is a 15 item questionnaire . The questionnaire measures Erectile Function (scored from 0-30), Intercourse satisfaction (0-15), orgasmic function (0-10), Sexual Desire (2-10) and Overall satisfaction (2-10). | From baseline (4 weeks before surgery) to 6 months after surgery | |
Primary | Change in EF | The International Index of Erectile Function (IIEF) will be administered. This is a 15 item questionnaire . The questionnaire measures Erectile Function (scored from 0-30), Intercourse satisfaction (0-15), orgasmic function (0-10), Sexual Desire (2-10) and Overall satisfaction (2-10). | From baseline (4 weeks before surgery) to 12 months after surgery | |
Primary | Change in EF | The International Index of Erectile Function (IIEF) will be administered. This is a 15 item questionnaire . The questionnaire measures Erectile Function (scored from 0-30), Intercourse satisfaction (0-15), orgasmic function (0-10), Sexual Desire (2-10) and Overall satisfaction (2-10). | From baseline (4 weeks before surgery) to 18 months after surgery | |
Primary | Change in EF | The Quality of Erection (QEL) questionnaire will be administered. This is a 6 item questionnaire addressing the patient's perception of erectile rigidity during sexual activity. It is scored from 0-100 with 100 indicating the highest quality erection | From baseline (4 weeks before surgery) to 3 months after surgery | |
Primary | Change in EF | The Quality of Erection (QEL) questionnaire will be administered. This is a 6 item questionnaire addressing the patient's perception of erectile rigidity during sexual activity. It is scored from 0-100 with 100 indicating the highest quality erection | From baseline (4 weeks before surgery) to 6 months after surgery | |
Primary | Change in EF | The Quality of Erection (QEL) questionnaire will be administered. This is a 6 item questionnaire addressing the patient's perception of erectile rigidity during sexual activity. It is scored from 0-100 with 100 indicating the highest quality erection | From baseline (4 weeks before surgery) to 12 months after surgery | |
Primary | Change in EF | The Quality of Erection (QEL) questionnaire will be administered. This is a 6 item questionnaire addressing the patient's perception of erectile rigidity during sexual activity. It is scored from 0-100 with 100 indicating the highest quality erection | From baseline (4 weeks before surgery) to 18 months after surgery | |
Primary | Change in Urinary function | The expanded prostate cancer index (EPIC-26) urinary domain will be administered. This is a 7 item questionnaire addressing the patient's perception of their urinary function over the previous 4 weeks. Higher scores indicate a greater degree of urinary dysfunction | From baseline (4 weeks before surgery) to 3 months after surgery | |
Primary | Change in Urinary function | The expanded prostate cancer index (EPIC-26) urinary domain will be administered. This is a 7 item questionnaire addressing the patient's perception of their urinary function over the previous 4 weeks. Higher scores indicate a greater degree of urinary dysfunction | From baseline (4 weeks before surgery) to 6 months after surgery | |
Primary | Change in Urinary function | The expanded prostate cancer index (EPIC-26) urinary domain will be administered. This is a 7 item questionnaire addressing the patient's perception of their urinary function over the previous 4 weeks. Higher scores indicate a greater degree of urinary dysfunction | From baseline (4 weeks before surgery) to 12 months after surgery | |
Primary | change in urinary function | The expanded prostate cancer index (EPIC-26) urinary domain will be administered. This is a 7 item questionnaire addressing the patient's perception of their urinary function over the previous 4 weeks. Higher scores indicate a greater degree of urinary dysfunction | From baseline (4 weeks before surgery) to 18 months after surgery | |
Secondary | change in health related quality of life | The RAND 12 questionnaire will be administered. This is a validated questionnaire evaluating the patient's perception of their overall health. | From baseline (4 weeks before surgery) to 3 months after surgery | |
Secondary | change in health related quality of life | The RAND 12 questionnaire will be administered. This is a validated questionnaire evaluating the patient's perception of their overall health. | From baseline (4 weeks before surgery) to 6 months after surgery | |
Secondary | change in health related quality of life | The RAND 12 questionnaire will be administered. This is a validated questionnaire evaluating the patient's perception of their overall health. | From baseline (4 weeks before surgery) to 12 months after surgery | |
Secondary | change in health related quality of life | The RAND 12 questionnaire will be administered. This is a validated questionnaire evaluating the patient's perception of their overall health. | From baseline (4 weeks before surgery) to 18 months after surgery | |
Secondary | change in sexual satisfaction | The EPIC-26 sexual domain questionnaire will be administered. This is a 9 item questionnaire used to evaluate the patient's perception of their sexual satisfaction over the previous 4 weeks. Higher scores indicate greater dissatisfaction and dysfunction | From baseline (4 weeks before surgery) to 3 months after surgery | |
Secondary | change in sexual satisfaction | The EPIC-26 sexual domain questionnaire will be administered. This is a 9 item questionnaire used to evaluate the patient's perception of their sexual satisfaction over the previous 4 weeks. Higher scores indicate greater dissatisfaction and dysfunction | From baseline (4 weeks before surgery) to 6 months after surgery | |
Secondary | change in sexual satisfaction | The EPIC-26 sexual domain questionnaire will be administered. This is a 9 item questionnaire used to evaluate the patient's perception of their sexual satisfaction over the previous 4 weeks. Higher scores indicate greater dissatisfaction and dysfunction | From baseline (4 weeks before surgery) to 12 months after surgery | |
Secondary | change in sexual satisfaction | The EPIC-26 sexual domain questionnaire will be administered. This is a 9 item questionnaire used to evaluate the patient's perception of their sexual satisfaction over the previous 4 weeks. Higher scores indicate greater dissatisfaction and dysfunction | From baseline (4 weeks before surgery) to 18 months after surgery | |
Secondary | Change in Body mass index (BMI) | From baseline (4 weeks before surgery) to 3 months after surgery | ||
Secondary | Change in Body mass index (BMI) | From baseline (4 weeks before surgery) to 6 months after surgery | ||
Secondary | Change in Body mass index (BMI) | From baseline (4 weeks before surgery) to 12 months after surgery | ||
Secondary | Change in Body mass index (BMI) | From baseline (4 weeks before surgery) to 18 months after surgery | ||
Secondary | Change in serum cholesterol level | From baseline (4 weeks before surgery) to 3 months after surgery | ||
Secondary | Change in serum cholesterol level | From baseline (4 weeks before surgery) to 6 months after surgery | ||
Secondary | Change in serum cholesterol level | From baseline (4 weeks before surgery) to 12 months after surgery | ||
Secondary | Change in serum cholesterol level | From baseline (4 weeks before surgery) to 18 months after surgery | ||
Secondary | Change in blood pressure (BP) | From baseline (4 weeks before surgery) to 3 months after surgery | ||
Secondary | Change in blood pressure (BP) | From baseline (4 weeks before surgery) to 6 months after surgery | ||
Secondary | Change in blood pressure (BP) | From baseline (4 weeks before surgery) to 12 months after surgery | ||
Secondary | Change in blood pressure (BP) | From baseline (4 weeks before surgery) to 18 months after surgery | ||
Secondary | Change in serum glucose | From baseline (4 weeks before surgery) to 3 months after surgery | ||
Secondary | Change in serum glucose | From baseline (4 weeks before surgery) to 6 months after surgery | ||
Secondary | Change in serum glucose | From baseline (4 weeks before surgery) to 12 months after surgery | ||
Secondary | Change in serum glucose | From baseline (4 weeks before surgery) to 18 months after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |